{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:50:45Z","timestamp":1789638645134,"version":"4.0.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"O'Bryan Gynecologic Precision Medicine Initiative"},{"name":"Translational Research Initiative in Gynecologic Cancers"},{"name":"Dwoskin Family Research Fund"},{"name":"Division of Gynecologic Oncology"},{"name":"Sylvester Comprehensive Cancer Center"},{"DOI":"10.13039\/100008530","name":"Miller School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ygyno.2019.12.033","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T08:56:08Z","timestamp":1579510568000},"page":"715-725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["Low-grade serous ovarian cancer: State of the science"],"prefix":"10.1016","volume":"156","author":[{"given":"Brian","family":"Slomovitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Malpica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ie-Ming","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Huntsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda N.","family":"Fader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel N.","family":"Grisham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0257-7327","authenticated-orcid":false,"given":"Matthew","family":"Schlumbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte C.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Ludemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail Austin","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider","family":"Mahdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwong K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Covens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Lecuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren P.","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taymaa","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Siemon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Llaurad\u00f3","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2019.12.033_bb0005","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.3802\/jgo.2018.29.e15","article-title":"Trends of low-grade serous ovarian carcinoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J Gyncol Oncol"},{"issue":"24","key":"10.1016\/j.ygyno.2019.12.033_bb0010","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","article-title":"Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor","volume":"33","author":"Gershenson","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"suppl_1","key":"10.1016\/j.ygyno.2019.12.033_bb0015","article-title":"Low-grade serous carcinoma of the ovary or peritoneum","volume":"27","author":"Gershenson","year":"2016","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2019.12.033_bb0020","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1002\/cncr.25929","article-title":"Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma","volume":"117","author":"Schlumbrecht","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.033_bb0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ygyno.2007.01.030","article-title":"Comparison of the clinical behavior of newly diagnosed stages II\u2013IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma","volume":"105","author":"Shvartsman","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.12.033_bb0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2010.10.033","article-title":"Is low-grade serous ovarian cancer part of the tumor spectrum of Hereditary Breast and Ovarian Cancer?","volume":"120","author":"Vineyard","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.033_bb0035","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/ijgc-2018-000018","article-title":"Low grade serous ovarian carcinoma: identifying variations in practice patterns","volume":"29","author":"Siemon","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.033_bb0040","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e4","article-title":"The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer","volume":"30","author":"Bogani","year":"2018","journal-title":"J. Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.033_bb0045","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0050","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1002\/1097-0142(20010615)91:12<2329::AID-CNCR1265>3.0.CO;2-U","article-title":"Neoadjuvant chemotherapy for unresectable ovaian cancer; a French multicenter study","volume":"91","author":"Ansquer","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2019.12.033_bb0055","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0090-8258(03)00249-X","article-title":"Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer","volume":"90","author":"Mazzeo","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.033_bb0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2014.11.005","article-title":"The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer","volume":"136","author":"Crane","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2019.12.033_bb0065","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"issue":"8","key":"10.1016\/j.ygyno.2019.12.033_bb0070","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/PAS.0b013e31803199b0","article-title":"Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma","volume":"31","author":"Malpica","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2019.12.033_bb0075","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/j.ygyno.2019.12.033_bb0080","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/PAS.0000000000000693","article-title":"Low-grade serous carcinoma of the ovary","volume":"40","author":"Ahn","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.033_bb0085","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/his.12046","article-title":"Fallopian tube precursors of ovarian low-and high-grade serous neoplasms","volume":"62","author":"Vang","year":"2013","journal-title":"Histopathol"},{"issue":"5","key":"10.1016\/j.ygyno.2019.12.033_bb0090","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/PAS.0000000000000615","article-title":"Ovarian low-grade serous carcinoma","volume":"40","author":"Okoye","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2019.12.033_bb0095","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0046-8177(90)90201-F","article-title":"Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases","volume":"21","author":"Bell","year":"1990","journal-title":"Hum. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.033_bb0100","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/PAS.0b013e31823732a9","article-title":"Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon","volume":"36","author":"Boyd","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"issue":"7","key":"10.1016\/j.ygyno.2019.12.033_bb0105","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/PAS.0b013e31802cbbe9","article-title":"The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis","volume":"31","author":"Dehari","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"issue":"5","key":"10.1016\/j.ygyno.2019.12.033_bb0110","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/PGP.0b013e31824ae6f2","article-title":"Low grade serous neoplasms of the ovary with transformation to high grade carcinomas: report of 3 cases","volume":"31","author":"Garg","year":"2012","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"6","key":"10.1016\/j.ygyno.2019.12.033_bb0115","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2559.2009.03283.x","article-title":"High-grade serous carcinoma arising in a low-grade serous carcinoma and micropapillary serous borderline tumour of the ovary in a 23-year-old woman","volume":"54","author":"Quddus","year":"2009","journal-title":"Histopathol"},{"issue":"5","key":"10.1016\/j.ygyno.2019.12.033_bb0120","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/PGP.0000000000000444","article-title":"An ovarian adenocarcinoma with combined low-grade serous and mesonephric morphologies suggests a M\u00fcllerian origin for some mesonephric carcinomas","volume":"37","author":"Chapel","year":"2018","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0125","first-page":"1","article-title":"Ovarian combined low-grade serous and mesonephric-like adenocarcinoma: further evidence for a Mullerian origin of mesonephric-like adenocarcinoma","volume":"0","author":"McCluggage","year":"2018","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"8","key":"10.1016\/j.ygyno.2019.12.033_bb0130","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/01.pas.0000166367.68459.7d","article-title":"An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2\/neu, and C-KIT in high-grade neoplasms","volume":"29","author":"O\u2019Neill","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2019.12.033_bb0135","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/pgp.0b013e31803025cd","article-title":"Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis","volume":"26","author":"Wong","year":"2007","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"6","key":"10.1016\/j.ygyno.2019.12.033_bb0140","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/PGP.0b013e31827630eb","article-title":"Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry","volume":"32","author":"Ali","year":"2013","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"9","key":"10.1016\/j.ygyno.2019.12.033_bb0145","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/modpathol.2013.55","article-title":"The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors","volume":"26","author":"Altman","year":"2013","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2019.12.033_bb0150","first-page":"250","article-title":"Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an ovarian tumor tissue analysis consortium study","volume":"4","author":"Rambau","year":"2018","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.033_bb0155","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.humpath.2012.07.010","article-title":"Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR","volume":"44","author":"B\u00f6sm\u00fcller","year":"2013","journal-title":"Hum. Pathol."},{"issue":"5","key":"10.1016\/j.ygyno.2019.12.033_bb0160","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317706230","article-title":"Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers","volume":"39","author":"Sadlecki","year":"2017","journal-title":"Tumor Biol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.033_bb0165","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/his.13651","article-title":"BRAFV 600E mutations and immunohistochemical expression of VE 1 protein in low-grade serous neoplasms of the ovary","volume":"73","author":"Turashvili","year":"2018","journal-title":"Histopathol"},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.033_bb0170","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.3967","article-title":"Low-grade serous carcinomas of the ovary contain very few point mutations","volume":"226","author":"Jones","year":"2012","journal-title":"J. Pathol."},{"issue":"35","key":"10.1016\/j.ygyno.2019.12.033_bb0175","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.5438","article-title":"Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes","volume":"6","author":"Hunter","year":"2015","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.ygyno.2019.12.033_bb0180","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1158\/0008-5472.CAN-16-2224","article-title":"EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas","volume":"77","author":"Etemadmoghadam","year":"2017","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.033_bb0185","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.27782","article-title":"BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer","volume":"119","author":"Grisham","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2019.12.033_bb0190","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","article-title":"BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas","volume":"177","author":"Wong","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/j.ygyno.2019.12.033_bb0195","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/bjc.2015.364","article-title":"Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum","volume":"113","author":"Gershenson","year":"2015","journal-title":"BJC"},{"issue":"2","key":"10.1016\/j.ygyno.2019.12.033_bb0200","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.ygyno.2019.12.033_bb0205","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1200\/JCO.2015.62.4726","article-title":"Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer","volume":"33","author":"Grisham","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0210","first-page":"1","article-title":"BRAF mutations in low-grade serous ovarian cancer and response to BRAF inhibition","volume":"2","author":"Moujaber","year":"2018","journal-title":"JCO Prec Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2019.12.033_bb0215","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ygyno.2012.10.013","article-title":"Quantification of ER\/PR expression in ovarian low-grade serous carcinoma","volume":"128","author":"Escobar","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2019.12.033_bb0220","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2019.12.033_bb0225","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/AOG.0b013e31829ce7ec","article-title":"Survival in women with grade 1 serous ovarian carcinoma","volume":"122","author":"Fader","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0230","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0235","author":"National Comprehensive Cancer Network"},{"issue":"10","key":"10.1016\/j.ygyno.2019.12.033_bb0240","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.033_bb0245","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.033_bb0250","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2019.04.010","article-title":"Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies","volume":"154","author":"Gaillard","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2019.12.033_bb0255","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0260","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.033_bb0265","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0270","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2019.06.011","article-title":"PARAGON: a phase II study of anastrozole in patients with estrogen receptoro-positive recurrent\/metastatic low-gade ovarian cancers and serous borderline tumors","volume":"154","author":"Tang","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.033_bb0275","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2017.01.027","article-title":"Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: a single institution experience","volume":"145","author":"Dalton","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0280","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IGC.0000000000000190","article-title":"Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer","volume":"24","author":"Grisham","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2019.12.033_bb0285","first-page":"874","article-title":"Tumor progression studied by analysis of cellular features of serial ascitic ovarian carcinoma tumors","volume":"43","author":"Mackillop","year":"1983","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0290","first-page":"3668","article-title":"Comparative properties of five human ovarian adenocarcinoma cell lines","volume":"45","author":"Buick","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0295","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1158\/0008-5472.CAN-04-3625","article-title":"Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations","volume":"65","author":"Pohl","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0300","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/0090-8258(87)90026-6","article-title":"Characterization of newly established human ovarian carcinoma cell line--special reference of the effects of cis-platinum on cellular proliferation and release of CA125","volume":"26","author":"Ishiwata","year":"1987","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0305","first-page":"6166","article-title":"Characterization and properties of nine human ovarian adenocarcinoma cell lines","volume":"48","author":"Langdon","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103988","article-title":"Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes","volume":"9","author":"Beaufort","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2019.12.033_bb0315","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.celrep.2018.10.096","article-title":"Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines","volume":"25","author":"Papp","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0320","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1186\/s12885-017-3716-4","article-title":"CAISMOV24, a new human low-grade serous ovarian carcinoma cell line","volume":"17","author":"da Silva","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2019.12.033_bb0325","first-page":"2235","article-title":"Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines","volume":"6","author":"Fernandez","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.12.033_bb0330","doi-asserted-by":"crossref","first-page":"e72162","DOI":"10.1371\/journal.pone.0072162","article-title":"Type-specific cell line models for type-specific ovarian cancer research","volume":"8","author":"Anglesio","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2019.12.033_bb0335","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12935-019-0725-1","article-title":"Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target","volume":"19","author":"Fernandez","year":"2019","journal-title":"Cancer Cell Int."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819318621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819318621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:50:10Z","timestamp":1758772210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819318621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0090825819318621"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.033","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-grade serous ovarian cancer: State of the science","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}